Search

Search Constraints

You searched for: Author/Creator Mørk, Cato

Search Results

1. HLA‐DQ2 is associated with anti‐drug antibody formation to infliximab in patients with immune‐mediated inflammatory diseases. (26th February 2023)

2. Risk factors for anti‐drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial. (26th April 2022)

3. Specific changes in conduction velocity recovery cycles of single nociceptors in a patient with erythromelalgia with the I848T gain-of-function mutation of Nav1.7. Issue 9 (September 2015)

4. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Issue 10086 (10th June 2017)